GALDERMA

EST. 1981

Last updated October 2023

Market Access at Galderma

As the emerging pure-play dermatology category leader, we are advancing dermatology for every skin story. Making our brands available to as many patients and consumers as possible across the full spectrum of dermatology through Injectable Aesthetics, Dermatological Skincare and Therapeutic Dermatology is therefore enshrined in our purpose.

Access to Medicine Programs

At Galderma, we are exploring ways to expand access to our brands to underserved patient populations through initiatives such as Galderma Care Connect or the Galderma Patient Assistance Program.

Clinical Trials and Early Access Programs

Galderma believes clinical trials are the most appropriate way for patients to access the investigational medical products we develop. These trials enable Galderma and the relevant regulatory agencies to rigorously assess the safety and efficacy of investigational medical products, so as to understand the associated benefits and risks and how the products should be used, including whether or not they should be approved as a therapy for their intended use. Obtaining regulatory approval enables Galderma to bring safe and effective investigational medical products to the greatest number of patients who may benefit from treatment.

Galderma recognizes that terminology for describing Early Access varies. The terminology used can include: Pre-Approval Access ("**PAA**"), Managed Access Programs ("**MAP**"), Expanded Access Programs ("**EAP**"), Compassionate Use, etc. Galderma defines this access as "Early Access". Currently, Galderma does not offer Early Access for the use of investigational medical products but is exploring introducing such programs for new treatments.

Galderma's Position on IP Protection

While Galderma maintains a global view with regard to intellectual property ("**IP**") protection, we do not file, maintain or enforce patents in any of the Least Developed Countries ("**LDC**s", as designated by the United Nations).